PMID: 6401594Mar 1, 1983Paper

A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

Cancer
G A OmuraL Leone

Abstract

A prospective randomized study was conducted in women with suboptimal (greater than or equal to 3 cm residual) Stage III, Stage IV, and recurrent ovarian adenocarcinoma to determine if combination chemotherapy is more effective than melphalan alone in achieving remission and improving survival. Of 233 evaluable patients with measurable disease, there were 64 treated with melphalan alone, of whom 20% achieved a clinical complete response and 17%, a partial response. Of the 97 patients receiving melphalan plus hexamethylmelamine, 28% achieved complete response compared with 32% of 72 patients given Adriamycin plus cyclophosphamide. The partial response rates for the combinations were 24% and 17%, respectively. The effect of these treatments was assessed in an additional 136 evaluable patients without measurable disease by progression-free interval and duration of survival. After statistically adjusting for distribution of cell type and grade, the clinical complete response rate for Adriamycin and cyclophosphamide (32%) in measurable cases was significantly higher (P = 0.04) than for melphalan alone. However, this combination did not improve median survival (12.3, 13.5, and 14.2 months, respectively, for M, M + H, and A + C). None...Continue Reading

References

Dec 1, 1979·Clinical Pharmacology and Therapeutics·D S AlbertsT E Moon
May 1, 1978·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M H TattersallA Weinberg

❮ Previous
Next ❯

Citations

Jul 1, 1994·Seminars in Surgical Oncology·G A Omura, B S Siller
Jan 1, 1984·Journal of Cancer Research and Clinical Oncology·C J Rodenburg, F J Cleton
Jan 1, 1984·Journal of Cancer Research and Clinical Oncology·R M Canetta, S K Carter
Oct 3, 2003·Current Oncology Reports·Maurie Markman
Aug 1, 1995·Critical Reviews in Oncology/hematology·P J Hoskins
Dec 14, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A du Bois
Aug 28, 2007·Nature Reviews. Cancer·Tracy Vargo-Gogola, Jeffrey M Rosen
Sep 16, 2010·Nature Reviews. Cardiology·Michael S Ewer, Steven M Ewer
Feb 21, 1985·The New England Journal of Medicine·G S RichardsonJ H Nelson
Feb 10, 2009·Journal of Toxicology and Environmental Health. Part a·Jong-Chul ParkByung Mu Lee
Oct 23, 2010·Journal of Toxicology and Environmental Health. Part a·Aramandla RameshMohammad S Niaz
Jan 1, 1985·Journal of Toxicology and Environmental Health·A J TobiaA Sagone
Feb 22, 2012·Clinical Obstetrics and Gynecology·Leigh G SeamonLarry J Copeland
Oct 1, 1990·The Australian and New Zealand Journal of Surgery·D M Francis
Jun 9, 2001·The Journal of Obstetrics and Gynaecology Research·P J DiSaia, K S Tewari
Aug 29, 2002·Cancer Investigation·Robert C ParkJohn M Weiner
Feb 1, 1995·Annals of Medicine·K Bertelsen
Nov 21, 1991·International Journal of Cancer. Journal International Du Cancer·Y J LidorR C Bast
Dec 17, 2015·Asia-Pacific Journal of Clinical Oncology·Jeffrey GohSally Baron-Hay
Oct 22, 2008·Seminars in Oncology·George A Omura, UNKNOWN Gynecologic Oncology Group
Apr 1, 2009·Seminars in Oncology·Carolyn Krasner, Linda Duska
Dec 1, 1986·Cancer Treatment Reviews·B J FosterD Hoth
Oct 1, 1988·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Z HernádiL G Lampé
Jan 1, 1992·Gynecologic Oncology·E PoplinD Alberts
Apr 1, 1985·European Journal of Cancer & Clinical Oncology·K AaboB L Sørensen
Jan 1, 1989·Journal of Surgical Oncology. Supplement·H D Homesley
Jan 1, 1987·Statistics in Medicine·R J Simes
Jan 1, 1995·Clinical Oncology : a Journal of the Royal College of Radiologists·K J Harrington, H E Lambert
Jun 17, 2015·Gynecologic Oncology·Victoria SopikSteven A Narod
May 5, 2001·Expert Opinion on Pharmacotherapy·G H Eltabbakh, C S Awtrey
Nov 5, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·Nelson Gustavo Neder Kalil, William Patrick McGuire
Feb 2, 2015·The Lancet Oncology·Michelle K WilsonAmit M Oza

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.